Capula Management Ltd Invests $154,000 in ImmunityBio, Inc. (NASDAQ:IBRX)

Capula Management Ltd acquired a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 60,101 shares of the company’s stock, valued at approximately $154,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp raised its stake in shares of ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares in the last quarter. Vanguard Group Inc. raised its position in ImmunityBio by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 17,328,229 shares of the company’s stock valued at $44,360,000 after acquiring an additional 425,713 shares in the last quarter. Clearwater Capital Advisors LLC raised its position in ImmunityBio by 75.4% during the fourth quarter. Clearwater Capital Advisors LLC now owns 846,419 shares of the company’s stock valued at $2,167,000 after acquiring an additional 363,870 shares in the last quarter. Barclays PLC lifted its stake in ImmunityBio by 127.4% in the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after acquiring an additional 202,248 shares during the last quarter. Finally, LPL Financial LLC increased its stake in shares of ImmunityBio by 67.2% during the 4th quarter. LPL Financial LLC now owns 257,449 shares of the company’s stock worth $659,000 after purchasing an additional 103,495 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Price Performance

ImmunityBio stock opened at $2.42 on Wednesday. ImmunityBio, Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $10.53. The firm has a fifty day moving average price of $3.07 and a two-hundred day moving average price of $3.56. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -2.63 and a beta of 0.51.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.11. The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $8.74 million. As a group, sell-side analysts expect that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IBRX has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of ImmunityBio in a report on Thursday, March 13th. BTIG Research initiated coverage on ImmunityBio in a report on Friday, January 10th. They set a “buy” rating and a $6.00 price objective on the stock. Finally, D. Boral Capital reissued a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a research note on Monday, March 31st. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $12.19.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.